Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?

With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth ...

Arrowhead hits 52-week high as late-stage trial win marks “derisking event”

Arrowhead Pharmaceuticals (ARWR) stock hits a 52-week high as analysts cheer a late-stage trial win for the company's ...
Las Vegas Sun

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran in patients with severe hypertriglyceridemia ...
The Manila Times

The 80/20 Institute CEO Bill Canady Releases The Rule of Three, Introducing a Leadership Framework for High-Performing Companies

In The Rule of Three, the operator behind $3 billion in shareholder value argues that growth stalls when the Visionary, the Operator, and the Prophet aren't all in place - and aligned ...